JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study
Affiliations
Affiliations
- Division of Neurology, Amiri Hospital, Sharq, Kuwait; Neurology clinic, Dasman Diabetes Institute, Dasman, Kuwait. Electronic address: alroughani@gmail.com.
- Department of Community Medicine & Behavioural Sciences, Faculty of Medicine, Kuwait University, Jabriya, Kuwait.
- Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Neurology and Psychiatry, Minia University, Minia, Egypt.
- Nehme and Therese Tohme MS Center, American University of Beirut Medical Center, Beirut, Lebanon.
- Department of Neurology, Ibn Sina Hospital, Kuwait City, Kuwait; Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait.
- MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
- King Abdullah International Medical Research Center, King Saud Ben Abdulaziz University for Health Sciences, NGHA, Riyadh, Saudi Arabia; Prince Mohammed bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia.
- Department of Neurology, American University of Beirut Medical Center.
Abstract
Objectives: To estimate JCV seroprevalence and risk of seroconversion against JCV among MS patients in the Middle East.
Methods: This multicenter study was conducted by implementing a cross-sectional design to assess JCV seroprevalence, and a longitudinal design to assess the risk of JCV seroconversion. Multivariable logistic and Poisson regression analyses were used to assess the relationship between clinical variables and JCV seropositivity and risk of seroconversion.
Results: Of 581 MS patients, 64.9% patients were females. Mean age and mean disease duration were 33.9 and 8.4years respectively. JCV seroprevalence was 48.7%. Male gender (p=0.002), age at onset (p=0.001) and disease duration of 20 or more years (p=0.007) were significantly associated with JCV seropositivity. Among patients (n=125), followed longitudinally, the risk of JCV seroconversion was 17.6% (95% CI: 11.4%-25.4%) during a median follow-up of 18months. The proportion of seroreverted and pseudoconverted patients was 4% and 3.2% respectively.
Conclusions: JCV seroprevalence among MS patients in the Middle East was lower than international figures. Male gender, age at onset and disease duration were significantly associated with JCV seropositivity. Risk of JCV seroconversion was higher than previously reported figures. Observed JCV sero-reversion or pseudo-conversion entail watchful period before embarking on a clinical decision.
Keywords: Epidemiology; JC virus; Middle-East; Multiple sclerosis; Prevalence; Seroconversion.
Similar articles
Aladro Y, Terrero R, Cerezo M, Ginestal R, Ayuso L, Meca-Lallana V, Millán J, Borrego L, Martinez-Ginés M, Rubio L, de Andrés C, Miralles A, Guijarro C, Rodríguez-García E, García-Dominguez JM, Muñoz-Fernández C, López de Silanes C, Gómez M, Thuissard I, Cerdán M, Palmí I, Díaz-Garzón LF, Meca-Lallana J.J Neurol Sci. 2016 Jun 15;365:16-21. doi: 10.1016/j.jns.2016.03.050. Epub 2016 Apr 2.PMID: 27206867
Anti-JC Virus Antibody Prevalence in Canadian MS Patients.
Bhan V, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, Walt L, Zhang A.Can J Neurol Sci. 2014 Nov;41(6):748-52. doi: 10.1017/cjn.2014.32. Epub 2014 Nov 4.PMID: 25377521
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D.Mult Scler. 2013 Oct;19(11):1533-8. doi: 10.1177/1352458513477925. Epub 2013 Mar 4.PMID: 23459571
Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV).
Knowles WA.Adv Exp Med Biol. 2006;577:19-45. doi: 10.1007/0-387-32957-9_2.PMID: 16626025 Review.
Paz SPC, Branco L, Pereira MAC, Spessotto C, Fragoso YD.Epidemiol Health. 2018 Jan 5;40:e2018001. doi: 10.4178/epih.e2018001. eCollection 2018.PMID: 29370683 Free PMC article. Review.
Cited by
Bonek R, Guenter W, Jałowiński R, Karbicka A, Litwin A, Maciejowski M, Zajdel R, Zajdel K, Petit V, Rejdak K.J Clin Med. 2021 May 6;10(9):1998. doi: 10.3390/jcm10091998.PMID: 34066624 Free PMC article.
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients.
Dwyer CM, Jokubaitis VG, Stankovich J, Baker J, Haartsen J, Butzkueven H, Cartwright A, Shuey N, Fragoso YD, Rath L, Skibina O, Fryer K, Butler E, Coleman J, MacIntrye J, Macdonell R, van der Walt A.Ther Adv Neurol Disord. 2021 Apr 16;14:1756286421998915. doi: 10.1177/1756286421998915. eCollection 2021.PMID: 33948117 Free PMC article.
JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients.
Bonek R, Guenter W, Jałowiński R, Karbicka A, Litwin A, Maciejowski M, Zajdel R, Petit V, Rejdak K.J Clin Med. 2020 Nov 27;9(12):3867. doi: 10.3390/jcm9123867.PMID: 33261210 Free PMC article.
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer M, Hegen H, Sellner J, Oppermann K, Bsteh G, Di Pauli F, Berger T, Deisenhammer F.Brain Behav. 2019 Jul;9(7):e01332. doi: 10.1002/brb3.1332. Epub 2019 Jun 6.PMID: 31168964 Free PMC article.
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E.Ann Clin Transl Neurol. 2018 Dec 9;6(2):252-262. doi: 10.1002/acn3.700. eCollection 2019 Feb.PMID: 30847358 Free PMC article.